Assignee
BEIJING HANMI PHARMACEUTICAL CO LTD
CN·11 granted patents·7 pending applications·27 citations·filing 2014–2023
Top patents by PatentIndex Score
18 records- 0185US9840517B2Compound inhibiting activities of BTK and/or JAK3 kinasesBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2014·Granted Dec 12, 2017·12 cites·6 claims
- 0283US10273242B2Compound inhibiting activities of BTK and/or JAK3 kinasesBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2017·Granted Apr 30, 2019·6 cites·9 claims
- 0382US11319378B2Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the sameBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2017·Granted May 3, 2022·3 cites·9 claims
- 0477US11498977B2Heterodimeric immunoglobulin constructs and preparation methods thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 15, 2022·2 cites·37 claims
- 0573US11753471B2Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing sameBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 12, 2023·1 cites·9 claims
- 0669US11827697B2Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Nov 28, 2023·1 cites·24 claims
- 0766US10562902B2IRAK4 inhibitor and use thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2016·Granted Feb 18, 2020·2 cites·6 claims
- 0856US2025277044A1Antibody specifically binding to 4-1bb and antigen-binding fragment of antibodyBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0955US2025361303A1Formulations for anti-pd-l1/anti-4-1bb bispecific antibodiesBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1055US2024301068A1Antibody specifically binding with pd-l1 and antigen-binding fragment of antibodyBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1155US2025277031A1Antibody specifically binding to cd47 and antigen-binding fragment thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1254US2024034801A1Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1354US2024052037A1Anti-pd-l1/anti-cd47 natural antibody structure-like heterodimeric form bispecific antibody and preparation thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1446US11739151B2Anti-PD-L1/anti-CD47 bispecific antibodyBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 29, 2023·0 cites·18 claims
- 1545US12325743B2Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method thereforBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2019·Granted Jun 10, 2025·0 cites·23 claims
- 1634US10322108B2N-benzoate group substituted benzopyrroline-2-one derivative and use thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2016·Granted Jun 18, 2019·0 cites·14 claims
- 1732US2016340422A1Bifunctional fusion protein, preparation method therefor, and use thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2015·Application pending·0 cites
- 1827US10988482B2IRAK4 inhibitor and use thereofBEIJING HANMI PHARMACEUTICAL CO LTD·Filed 2015·Granted Apr 27, 2021·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when BEIJING HANMI PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →